Calliditas Therapeutics AB (publ) EBITDA 2011-2026 | CALT

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Calliditas Therapeutics AB (publ)

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-524 M	-377 M	-26.1 M	-133 M	-84.6 M	-56.4 M	-51.3 M	-	-	-	-

All numbers in SEK currency

Indicator range from annual reports

Maximum	Minimum	Average
-26.1 M	-524 M	-179 M

Quarterly EBITDA Calliditas Therapeutics AB (publ)

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-208 M	-	-	-159 M	-151 M	-	-	-66.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in SEK currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-66.6 M	-208 M	-146 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Drug manufacturers industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Aurora Cannabis ACB	-283 M	$ 3.45	0.58 %	$ 86.3 M	Canada
Alimera Sciences ALIM	6.82 M	-	-	$ 142 M	USA
Adamis Pharmaceuticals Corporation ADMP	-23.6 M	-	0.86 %	$ 117 M	USA
Aerie Pharmaceuticals AERI	-40 M	-	-	$ 754 M	USA
AcelRx Pharmaceuticals ACRX	-16.6 M	-	7.5 %	$ 6.35 M	USA
Canopy Growth Corporation CGC	-95.6 M	$ 1.02	-	$ 110 M	Canada
Agile Therapeutics AGRX	-19.8 M	-	10.11 %	$ 58.2 M	USA
Cronos Group CRON	-176 M	$ 2.54	1.6 %	$ 1.33 B	Canada
Assertio Holdings ASRT	8.47 M	$ 11.77	1.99 %	$ 836 M	USA
DURECT Corporation DRRX	-36.9 M	-	-	$ 50.1 M	USA
Avadel Pharmaceuticals plc AVDL	-39.7 M	-	-	$ 2.06 B	France
Eagle Pharmaceuticals EGRX	81.6 M	-	-39.89 %	$ 27.7 M	USA
Evolus EOLS	-25.2 M	$ 5.04	0.6 %	$ 325 M	USA
Evoke Pharma EVOK	-7.43 M	-	-	$ 36.6 M	USA
HEXO Corp. HEXO	-85.5 M	-	2.45 %	$ 38.1 M	Canada
Catalent CTLT	-260 M	-	-	$ 11.5 B	USA
Cumberland Pharmaceuticals CPIX	3.06 M	$ 3.06	0.66 %	$ 43 M	USA
Jupiter Wellness JUPW	429 K	-	-	$ 33.6 M	USA
Athenex ATNX	-65.5 M	-	-23.39 %	$ 1.76 M	USA
Endo International plc ENDP	306 M	-	-	$ 28.9 M	Irlanda
Harrow Health HROW	31.8 M	$ 34.91	2.38 %	$ 1.28 B	USA
Emergent BioSolutions EBS	-601 M	$ 8.33	3.22 %	$ 426 M	USA
OrganiGram Holdings OGI	-91.8 M	$ 1.42	0.71 %	$ 402 M	Canada
China Pharma Holdings CPHI	-1.97 M	$ 0.62	2.94 %	$ 10.8 M	China
Sundial Growers SNDL	-132 M	$ 1.44	-4.64 %	$ 3.37 M	Canada
Organogenesis Holdings ORGO	12.3 M	$ 2.58	-2.27 %	$ 340 M	USA
Pacira BioSciences PCRX	5.41 M	$ 22.69	-2.45 %	$ 1.05 B	USA
ProPhase Labs PRPH	28.3 M	-	-	$ 5.07 M	USA
Lannett Company LCI	-142 M	-	1.15 %	$ 7.11 M	USA
Radius Health RDUS	-53.2 M	-	-	$ 1.42 B	USA
Perrigo Company plc PRGO	-785 M	$ 9.72	4.4 %	$ 1.35 B	USA
Neoleukin Therapeutics NLTX	-52.3 M	-	-	$ 193 M	Canada
Sonoma Pharmaceuticals SNOA	-3.57 M	$ 2.4	-2.24 %	$ 2.98 M	USA
Relmada Therapeutics RLMD	-104 M	$ 6.18	4.57 %	$ 186 M	USA
Rockwell Medical RMTI	-5.23 M	$ 0.96	6.61 %	$ 22.4 M	USA
PetIQ PETQ	81.6 M	-	1.64 %	$ 400 M	USA
OptiNose OPTN	-22.3 M	-	-	$ 1.08 B	USA
PLx Pharma PLXP	-40.7 M	-	-27.8 %	$ 2.56 M	USA
SCYNEXIS SCYX	-16.1 M	$ 0.9	4.68 %	$ 44.9 M	USA
Recro Pharma REPH	4.65 M	-	-4.76 %	$ 65.3 M	USA
TherapeuticsMD TXMD	-7.6 M	$ 2.17	-	$ 22.7 M	USA
Solid Biosciences SLDB	-127 M	$ 7.48	2.33 %	$ 305 M	USA
Veru VERU	-36.6 M	$ 2.37	-0.84 %	$ 320 M	USA
Tilray TLRY	-1.37 B	$ 6.9	0.15 %	$ 4.26 B	Canada
Viatris VTRS	3.51 B	$ 13.51	-	$ 16.2 B	USA
Tricida TCDA	-153 M	-	-	$ 3.25 M	USA
cbdMD YCBD	-2.86 M	$ 0.72	1.41 %	$ 3.11 M	USA
Zynerba Pharmaceuticals ZYNE	-35 M	-	-	$ 55.5 M	USA
Zomedica Corp. ZOM	-82.3 M	-	-0.21 %	$ 98 M	USA